• Explore /
  • Poster
  • / Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).

Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).

Abstract Poster

Authors

null

Xiaofeng Chen

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;

Xiaofeng Chen , Deqiang Wang , Yuan Yuan , Jie Tang , Fen Guo , Yizhang Chen , Junli Ding , Tingting Hong , Binbin Lu , Wei Li , Rong Wang , Yitong Tian , Lanlan Pan , Jiaguang Zhang , Xinyi Zhang , Tongpeng Xu , Hao Xu , Yongqian Shu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04963088

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 396)

DOI

10.1200/JCO.2023.41.4_suppl.396

Abstract #

396

Poster Bd #

G18

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Jiafu Ji

First Author: Lin Shen

First Author: Yelena Y. Janjigian